Intervet Canada Ltd. has announced the registration of Circumvent^™ PCV vaccine for use in the prevention of PCV2 (Porcine Circovirus, type 2) infection in pigs.

Circumvent^™ PCV, a proven efficacious vaccine against circovirus infection (PCVAD – Porcine Circovirus Associated Diseases), is now fully licensed in Canada and the US.  This product has been available in limited quantities since spring 2006 through emergency use provisions to assist in the circovirus emerging disease crisis.

“Circumvent^™ PCV has saved a lot of bacon”, said Dr. Jorgen Jorgensen, General Manager of Intervet Canada. “Two years ago we received the first supply of this product to be tested in Canada. It wasn’t long before we witnessed significant results. Mortality rates of 40 to 50% were reduced dramatically down to low single digits.”

“Veterinarians and producers are also seeing secondary benefits when vaccinating with Circumvent^™ PCV,” said Dr. Jorgensen.  “Along with the dramatic decrease in mortality, producers are also experiencing better growth rates, heavier pigs and healthier herds.  The use of antibiotics has been reported to have dropped, even in the presence of PRRS and feed gain has improved, demonstrating that the investment of vaccination is returned many times,” said Dr. Jorgensen.

Circumvent^™ PCV is registered for use in healthy swine, three weeks of age or older, as an aid in the prevention of viremia and virus shedding caused by Porcine Circovirus, type 2.

For additional product, technical or order information please contact your Intervet Technical Sales Representative, log on to www.intervet.ca or call 1-800-268-4257.